The Cancer Letter

Inside information on cancer research and drug development

Vol.
36
No.
9
September 27, 2013Sep 27, 2013
Free
DOWNLOAD THE PDF

RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

ODAC Votes 13:0 For Approving Perjeta

Early Treatment with CMX001 Can Help Prevent CMV Infection

Researchers Identify Mutation Linked to Inherited Risk of ALL

Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia

Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function

Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy

Long-term Hormonal Therapy Adds No Additional Benefits

NCI CTEP Approved Trials For the Month of September

FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer

Login

Looking for IP Login?